Cibinetide
Also known as: ARA 290, ARA-290, ARA‑290, Cibinetide, HBSP, Helix B surface peptide
Source Cibinetide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Cibinetide (also known as ARA‑290) is an 11‑amino‑acid peptide derived from helix B of erythropoietin. It is being studied for its ability to reduce inflammation and promote tissue repair in conditions such as diabetic peripheral neuropathy and sarcoidosis.
Mechanism of Action
Selective activation of the innate repair receptor (EPOR‑CD131 heteroreceptor) leading to anti‑inflammatory and tissue‑protective signaling without stimulating erythropoiesis
Routes of Administration
Goals & Uses
- Ischemia‑reperfusion injuryTissue ProtectionLow
- Metabolic improvement in type 2 diabetes-associated neuropathyMetabolic / EndocrineLow
- Reduction of painful small fiber neuropathy symptomsNeurological / PainModerate
- Neuroprotection and nerve fiber regenerationNeurologicalModerate
- SarcoidosisInflammatory DiseaseModerate
- Anti-inflammatory effects in sarcoidosisInflammatory / AutoimmuneModerate
- Diabetic peripheral neuropathyNeuropathyModerate
- Ischemia-reperfusion organ protectionOrgan ProtectionLow
Contraindications
- Active malignancyOncologyModerateUse caution or avoid depending on agent and context
- Known hypersensitivity to cibinetide or excipientsAllergy / HypersensitivityHigh
Adverse Effects
- Injection site reactionsLocalCommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- FatigueGeneralUncommonLow energy or tiredness
- Injection site erythemaLocalCommonRedness at the injection site
Drug Interactions
- Immunosuppressants (e.g., corticosteroids, methotrexate)Low
- Erythropoiesis-stimulating agents (ESAs)Low
- Erythropoiesis‑stimulating agentsLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatrics (<12 y)AgeRelative
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Patients with known thromboembolic riskCardiovascularRelative
Regulatory Status
- European UnionInvestigationalClinical trial authorisation pending
- RUInvestigationalPhase II study conducted in Russia
- United StatesInvestigationalIND in place; Phase II/III trials ongoing
- United KingdomUnknownNo confirmed regulatory designation or approval in the UK post-Brexit; status follows EMA precedent historically.
Not approved by FDA, EMA or other major agencies; currently in Phase II/III clinical trials in several countries.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Cibinetide?
Cibinetide (also known as ARA‑290) is an 11‑amino‑acid peptide derived from helix B of erythropoietin. It is being studied for its ability to reduce inflammation and promote tissue repair in conditions such as diabetic peripheral neuropathy and sarcoidosis.
What is Cibinetide used for?
Cibinetide is educationally associated with: Ischemia‑reperfusion injury, Metabolic improvement in type 2 diabetes-associated neuropathy, Reduction of painful small fiber neuropathy symptoms, Neuroprotection and nerve fiber regeneration, Sarcoidosis, Anti-inflammatory effects in sarcoidosis, Diabetic peripheral neuropathy, Ischemia-reperfusion organ protection. Educational only — not medical advice.
How is Cibinetide administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Cibinetide?
Reported adverse effects include: Injection site reactions, Headache, Nausea, Fatigue, Injection site erythema. This list is not exhaustive — consult a qualified clinician.
Who should avoid Cibinetide?
Recorded contraindications: Active malignancy, Known hypersensitivity to cibinetide or excipients. Consult a qualified clinician before use.